Sphere Fluidics appoints Edward Rayner as Non-Executive Director

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Ed Rayner to its Board of Directors as a Non-Executive Director. Leveraging extensive experience in fundraising and investment within the life sciences and technology sectors, Ed’s appointment will strengthen the Company’s strategic vision as it progresses ambitious plans for future growth and commercial success.

Throughout his career, Ed has held a number of key analyst and portfolio management positions at leading research-led investment firms, including AMP Capital, Alliance Bernstein, UBS Asset Management and JP Morgan Investment Management. He has worked across a broad range of sectors, including healthcare and technology, in addition to managing equity portfolios, running a research team, and launching a small companies fund. More recently, Ed worked in biotech venture capital at Arix Bioscience and, in that role, represented the fund as an NED for various Life Sciences companies, including Pharmaxis, Depixus, and Simbec Orion Group. In his current role as a Healthcare Consultant for investment bank Panmure Gordon, he works with private Life Sciences companies to raise capital. He has an MA in Chemistry and MSc in Management from Oxford University, and is a Chartered Financial Analyst.

We’re very pleased that Ed has joined the Sphere Fluidics Board. He has an excellent international investment banking background blended with experience from leading investment funds. His acumen will help us map out our growth plans, competitive positioning and a strong exit.”

Dr. Frank F. Craig, CEO, Sphere Fluidics

Ed Rayner, Non-Executive Board Director, Sphere Fluidics, added: “I’m excited to join the Sphere Fluidics Board to support the Company as it accelerates its commercial roll out. The multi-disciplinary science and engineering teams have developed a ground-breaking suite of products that can make a huge difference to the success of drug development programmes.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sphere Fluidics. (2024, April 18). Sphere Fluidics appoints Edward Rayner as Non-Executive Director. News-Medical. Retrieved on May 22, 2024 from https://www.news-medical.net/news/20240418/Sphere-Fluidics-appoints-Edward-Rayner-as-Non-Executive-Director.aspx.

  • MLA

    Sphere Fluidics. "Sphere Fluidics appoints Edward Rayner as Non-Executive Director". News-Medical. 22 May 2024. <https://www.news-medical.net/news/20240418/Sphere-Fluidics-appoints-Edward-Rayner-as-Non-Executive-Director.aspx>.

  • Chicago

    Sphere Fluidics. "Sphere Fluidics appoints Edward Rayner as Non-Executive Director". News-Medical. https://www.news-medical.net/news/20240418/Sphere-Fluidics-appoints-Edward-Rayner-as-Non-Executive-Director.aspx. (accessed May 22, 2024).

  • Harvard

    Sphere Fluidics. 2024. Sphere Fluidics appoints Edward Rayner as Non-Executive Director. News-Medical, viewed 22 May 2024, https://www.news-medical.net/news/20240418/Sphere-Fluidics-appoints-Edward-Rayner-as-Non-Executive-Director.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows